NCT04492033 - A Study of CTX-009 (ABL001) in Combination With Irinotecan or Paclitaxel in Advanced or Metastatic Solid Tumor Patients | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 22, 2020

Primary Completion Date

January 8, 2024

Study Completion Date

January 9, 2025

Conditions

P1b: Advanced Solid TumorsP2: Biliary Tract Cancer

Interventions

DRUG

CTX-009 (ABL001)

CTX-009 (ABL001) will be administered biweekly.

DRUG

Paclitaxel

Paclitaxel will be administered weekly.

DRUG

Irinotecan

Irinotecan will be administered biweekly.

Trial Locations (4)

Seoul National University Bundang Hospital, Seongnam-si

Asan Medical Center, Seoul

Samsung Medical Center, Seoul

Seoul National University Hospital, Seoul